Organisation paid for research Program year 2025 Source: CMS Open Payments

All Medical Research

Neither a doctor nor a teaching hospital

Research payments

$467,458

39 payments

Through program year 2025, All Medical Research is reported as receiving $467,458 in research payments, across 39 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $170,889 4
2024 Research $65,348 2
2021 Research $53,468 10
2020 Research $56,793 11
2019 Research $120,960 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $235,218 33 payments
  2. AstraZeneca Pharmaceuticals LP $185,292 5 payments
  3. Novartis Pharmaceuticals Corporation $46,948 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. M16-100 $176,230 22 payments
  2. A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension $147,168 2 payments
  3. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $53,468 10 payments
  4. A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $46,948 1 payment
  5. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $36,601 2 payments
  6. A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism $5,520 1 payment
  7. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $1,523 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record